When GLP -1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) started gaining traction in obesity management, I have to admit I was skeptical. I have always practiced with a food first approach and feel that weight loss can effectively be achieved through diet and exercise. However GLP-1 receptor agonists have emerged as game-changers in the treatment of obesity and related metabolic conditions.